SG11201908871SA - Fused pentacyclic imidazole derivatives as modulators of tnf activity - Google Patents

Fused pentacyclic imidazole derivatives as modulators of tnf activity

Info

Publication number
SG11201908871SA
SG11201908871SA SG11201908871SA SG11201908871SA SG 11201908871S A SG11201908871S A SG 11201908871SA SG 11201908871S A SG11201908871S A SG 11201908871SA SG 11201908871S A SG11201908871S A SG 11201908871SA
Authority
SG
Singapore
Prior art keywords
ipd
disorders
ucb
international
bath road
Prior art date
Application number
Other languages
English (en)
Inventor
Daniel Christopher Brookings
Haro Garcia Teresa De
Yann Foricher
Helen Tracey Horsley
Martin Clive Hutchings
James Andrew Johnson
Malcolm Maccoss
Mengyang Xuan
Zhaoning Zhu
Original Assignee
Ucb Biopharma Sprl
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201908871S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl, Sanofi Sa filed Critical Ucb Biopharma Sprl
Publication of SG11201908871SA publication Critical patent/SG11201908871SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201908871S 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity SG11201908871SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (1)

Publication Number Publication Date
SG11201908871SA true SG11201908871SA (en) 2019-10-30

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908871S SG11201908871SA (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Country Status (32)

Country Link
US (4) US10980814B2 (cg-RX-API-DMAC7.html)
EP (2) EP3939980B1 (cg-RX-API-DMAC7.html)
JP (2) JP7083358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102565132B1 (cg-RX-API-DMAC7.html)
CN (1) CN110582495B (cg-RX-API-DMAC7.html)
AR (1) AR111426A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018259040B2 (cg-RX-API-DMAC7.html)
CL (1) CL2019002875A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012856A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190526A (cg-RX-API-DMAC7.html)
DK (1) DK3615534T3 (cg-RX-API-DMAC7.html)
EA (1) EA039049B1 (cg-RX-API-DMAC7.html)
ES (2) ES2893807T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211927T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056593T2 (cg-RX-API-DMAC7.html)
IL (1) IL269890B (cg-RX-API-DMAC7.html)
LT (1) LT3615534T (cg-RX-API-DMAC7.html)
MA (2) MA49055B1 (cg-RX-API-DMAC7.html)
MX (1) MX2019012443A (cg-RX-API-DMAC7.html)
MY (1) MY197212A (cg-RX-API-DMAC7.html)
PE (1) PE20200662A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502182B1 (cg-RX-API-DMAC7.html)
PL (2) PL3939980T3 (cg-RX-API-DMAC7.html)
PT (2) PT3615534T (cg-RX-API-DMAC7.html)
PY (1) PY1829804A (cg-RX-API-DMAC7.html)
RS (1) RS62596B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908871SA (cg-RX-API-DMAC7.html)
SI (1) SI3615534T1 (cg-RX-API-DMAC7.html)
TW (1) TWI801378B (cg-RX-API-DMAC7.html)
UY (1) UY37700A (cg-RX-API-DMAC7.html)
WO (1) WO2018197503A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906255B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219609B (zh) * 2016-04-01 2022-02-01 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合六环咪唑衍生物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3117344A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
JP2025540024A (ja) 2022-11-23 2025-12-11 フォワード セラピューティクス, インコーポレイテッド TNF-α活性の調節因子
WO2024223740A1 (en) 2023-04-26 2024-10-31 Sanofi Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
EP4739695A1 (en) 2023-07-04 2026-05-13 Sanofi Crystalline form
WO2025038927A1 (en) 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof
CN121925420A (zh) 2023-09-29 2026-04-24 赛诺菲 作为tnf活性的调节剂的桥联五环咪唑衍生物的制备、中间体及其制备
WO2025201449A1 (zh) * 2024-03-27 2025-10-02 海思科医药集团股份有限公司 一种杂环衍生物及其在医药上的应用
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
TW202604511A (zh) * 2024-04-17 2026-02-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用
WO2026012303A1 (en) * 2024-07-09 2026-01-15 Hangzhou Highlightll Pharmaceutical Co., Ltd NOVEL BENZO [4, 5] IMIDAZO COMPOUNDS AS TNFα MODULATORS
WO2026022134A1 (en) 2024-07-23 2026-01-29 Sanofi Novel aminocarbonylation processes
WO2026021586A1 (zh) * 2024-07-26 2026-01-29 上海瀚辰星泰医药科技有限公司 一种多环化合物及其制备方法和应用
WO2026027449A1 (en) 2024-07-29 2026-02-05 Sanofi Fused pentacyclic imidazole derivatives
TW202611047A (zh) * 2024-09-04 2026-03-16 大陸商蘇州湃玥生物科技有限公司 一種作為tnf活性調節劑的稠合五環苯並咪唑衍生物及其製備方法和應用
WO2026055519A1 (en) 2024-09-06 2026-03-12 Rapt Therapeutics, Inc. Fused ring imidazole compounds
WO2026064602A1 (en) * 2024-09-23 2026-03-26 Synnovation Therapeutics, Inc. HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFα ACTIVITY
WO2026068677A1 (en) 2024-09-27 2026-04-02 Sanofi Processes for the preparation of fused pentacyclic imidazoles and intermediates
WO2026112363A1 (en) 2024-11-21 2026-05-28 Rapt Therapeutics, Inc. Fused heterocyclic aromatic compounds and uses thereof
WO2026145487A1 (zh) * 2024-12-30 2026-07-09 上海翊石医药科技有限公司 一类芳杂环化合物及其制备方法和应用
WO2026145553A1 (zh) * 2024-12-30 2026-07-09 无锡奕拓医药科技有限责任公司 多环类化合物、其药物组合物及其应用
WO2026145577A1 (zh) * 2024-12-31 2026-07-09 无锡奕拓医药科技有限责任公司 桥环类化合物、其药物组合物及其应用
WO2026146204A1 (en) 2025-01-03 2026-07-09 Ablynx Nv Compounds, constructs and compositions targeting tnf and ox40l for use in the treatment of type 1 diabetes
WO2026149469A1 (zh) * 2025-01-08 2026-07-16 上海瀚辰星泰医药科技有限公司 一种多环化合物及其制备方法和应用
WO2026158438A1 (zh) * 2025-01-24 2026-07-30 苏州朗睿生物医药有限公司 一种五环衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2885432T3 (es) 2014-10-03 2021-12-13 Ucb Biopharma Sprl Derivados de imidazol pentacíclicos condensados
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Also Published As

Publication number Publication date
CN110582495A (zh) 2019-12-17
BR112019020314A2 (pt) 2020-04-28
TWI801378B (zh) 2023-05-11
HRP20211927T1 (hr) 2022-03-18
US20210252012A1 (en) 2021-08-19
US20250127795A1 (en) 2025-04-24
EP3939980B1 (en) 2023-07-26
SI3615534T1 (sl) 2022-01-31
ES2956555T3 (es) 2023-12-22
TW201841918A (zh) 2018-12-01
CL2019002875A1 (es) 2020-03-06
EP3615534B1 (en) 2021-09-15
LT3615534T (lt) 2021-11-25
EP3939980A1 (en) 2022-01-19
MY197212A (en) 2023-06-01
ZA201906255B (en) 2021-01-27
JP2022116233A (ja) 2022-08-09
EP3615534A1 (en) 2020-03-04
MX2019012443A (es) 2020-01-13
DK3615534T3 (da) 2021-10-18
HUE056593T2 (hu) 2022-02-28
PH12019502182A1 (en) 2020-06-08
CA3058980A1 (en) 2018-11-01
AR111426A1 (es) 2019-07-10
PL3939980T3 (pl) 2024-02-05
MA49055B1 (fr) 2021-12-31
CR20190526A (es) 2020-01-07
PL3615534T3 (pl) 2022-01-31
EA201992407A1 (ru) 2020-04-06
RS62596B1 (sr) 2021-12-31
PT3615534T (pt) 2021-10-21
PH12019502182B1 (en) 2024-01-31
MA49055A (fr) 2021-05-05
JP7083358B2 (ja) 2022-06-10
UY37700A (es) 2018-11-30
WO2018197503A1 (en) 2018-11-01
IL269890B (en) 2022-03-01
CN110582495B (zh) 2022-04-01
PT3939980T (pt) 2023-08-07
CO2019012856A2 (es) 2020-01-17
EA039049B1 (ru) 2021-11-26
US10980814B2 (en) 2021-04-20
AU2018259040B2 (en) 2022-04-28
ES2893807T3 (es) 2022-02-10
MA57699B1 (fr) 2023-11-30
PY1829804A (es) 2019-03-01
KR20190141200A (ko) 2019-12-23
AU2018259040A1 (en) 2019-10-31
KR102565132B1 (ko) 2023-08-08
JP7299382B2 (ja) 2023-06-27
PE20200662A1 (es) 2020-06-11
JP2020517637A (ja) 2020-06-18
US20230250105A1 (en) 2023-08-10
NZ758198A (en) 2024-01-26
US20200046723A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
SG11201900482SA (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201408261UA (en) Syringe
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201900596XA (en) Cannabis composition
CA2859619C (en) Bromodomain inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201900501RA (en) Cannabis composition
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201407372UA (en) Nampt inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907199QA (en) Cancer treatment
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201908159QA (en) Dual magl and faah inhibitors
SG11201908052PA (en) Lipid-based nanoparticles with enhanced stability
SG11201805755SA (en) Methods of administering hepcidin
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201808650QA (en) Methods of treating ocular conditions
SG11201900043TA (en) Antibody formulations
SG11201907153RA (en) Topical formulations and methods
SG11201907844TA (en) Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders